Hims & Hers health chief legal officer sells $251,984 in stock

SAN FRANCISCO—Boughton Soleil, Chief Legal Officer of Hims & Hers Health, Inc. (NYSE:HIMS), recently sold a significant portion of the company’s stock. According to a Form 4 filing with the Securities and Exchange Commission, Soleil sold 4,152 shares of Class A common stock on February 18, 2025, at a price of $60.69 per share. This transaction totaled $251,984. InvestingPro analysis indicates the stock is currently trading above its Fair Value, with multiple metrics suggesting overbought conditions.

Following the sale, Soleil holds 157,345 shares of the company. The transaction was conducted under a pre-arranged trading plan, as indicated in the filing. The sale reflects part of Soleil’s ongoing management of personal financial affairs while maintaining a substantial investment in the now $14.4 billion market cap company, which maintains a GREAT financial health rating according to InvestingPro’s comprehensive analysis. For deeper insights into insider trading patterns and 18 additional ProTips, explore the full HIMS research report on InvestingPro.

In other recent news, Hims & Hers Health, Inc. has reported significant developments that could impact investor decisions. The company experienced a 104% increase in online sales year-over-year for January, according to Bloomberg Second Measure data. Analysts at BofA Securities have projected that the first quarter of 2025 could see online revenue ranging between $551 million and $574 million, which surpasses the Visible Alpha consensus estimate of $489.4 million. Despite these positive forecasts, BofA Securities maintains an Underperform rating, though they have raised the price target from $18 to $21.

Additionally, Hims & Hers has acquired Trybe Labs, an at-home lab testing facility, to enhance personalized healthcare offerings. This acquisition is anticipated to improve clinical decision-making and support personalized treatments by providing a broader range of data and biomarkers. The financial terms of the acquisition were not disclosed, but it was funded with cash on hand.

In terms of analyst ratings, Canaccord Genuity has increased the price target for Hims & Hers to $68, maintaining a Buy rating. BTIG has also raised its price target significantly to $85, reiterating a Buy rating. Both firms express optimism about the company’s growth prospects and its ability to expand its healthcare offerings. These recent developments indicate a dynamic period for Hims & Hers, with analysts showing varying levels of confidence in the company’s future performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.